This study is testing different treatments for a type of blood cancer called BCR-ABL-Positive Acute Lymphoblastic Leukemia (ALL) in adults. The researchers want to see if adding a drug called blinatumomab to the usual treatment, which includes chemotherapy, steroids (medicines that reduce inflammation), and a tyrosine kinase inhibitor (TKI, a medicine that blocks cancer growth), works better. Blinatumomab is a special medicine that helps the body's immune system attack cancer. The study will also look at how long patients live, how well the cancer is controlled, and any side effects from the treatments.

Key Points:

• Duration: This study involves multiple cycles of 21-28 days, with follow-up visits for up to 10 years.
• Procedures: Participants will have several tests like bone marrow biopsies and scans.
• Eligibility: Participants must be 18-75 years old, not pregnant, and meet certain health criteria.